Extrapolation of survival data plays a vital role in the evaluation of anti-tumor pharmacoeconomics, but it has not been standardized in the evaluation guide of pharmacoeconomics in China. It aims to sort out the relevant international norms of extrapolation of survival data and clarify the current research situation of extrapolation of survival data in the economic evaluation of antitumor drugs in China, in order to provide reference suggestions for the more standardized development of extrapolation of survival data in China.